fda compounding semaglutide enforcement 2025 news Compound versions of GLP-1 drugs for weight loss halted by FDA Update: Current Guidelines for

Retatrutide remains a research-stage compound

In phase 2 trial data published in The New England Journal of Medicine (2023), retatrutide demonstrated substantial weight loss in adults with obesity with some participants losing over 20% of their body weight over approximately 48 weeks

Monitor how you feel and note any side effects

Brand claims regarding effectiveness, mechanism, and manufacturing are attributed to the brand and are not independently verified

2

It also delivers prebiotic fiber that feeds the microbiome through slow fermentation to support colonization of skinny gut bacteria Akkermansia and Bifidobacterium